Quantcast

Once-daily ciprofloxacin clears urinary infection

November 17, 2005

By David Douglas

NEW YORK (Reuters Health) – Once-daily use of a new
extended release (ER) formulation of the antibiotic
ciprofloxacin is as effective as twice-daily
intermediate-release (IR) ciprofloxacin in clearing up urinary
infection in women, according to researchers.

Ciprofloxacin ER (brand name Proquin XR, made by Depomed)
“showed efficacy that was clearly at least as good as
ciprofloxacin IR twice daily,” investigator Dr. Bret Berner
told Reuters Health.

Dr. Berner, of Depomed Inc., Menlo Park, California, and
colleagues note in the medical journal Antimicrobial Agents and
Chemotherapy that by reducing the release rate of
ciprofloxacin, the ER formulation may cause fewer stomach
upsets and so patients may be more likely to stick with the
treatment

To investigate, the researchers studied 272 women with
uncomplicated urinary infection who were assigned to take the
ER formulation daily for three days. A further 257 women were
given the IR formulation (CIPRO, Bayer) to take twice daily for
three days.

Clinical cure rates at up to 11 days after treatment were
85.7 percent in the ER group and 86.1 percent in the IR group.

Both treatments were well tolerated but the frequency of
nausea in the ER group (0.6 percent) was significantly lower
than that in the IR patients (2.2 percent). This was also true
of diarrhea (0.2 percent versus 1.2 percent).

“Ciprofloxacin ER has such a low incidence of nausea and
diarrhea that is the only marketed fluoroquinolone where the
label treats these as uncommon adverse events,” Berner
commented.

SOURCE: Antimicrobial Agents and Chemotherapy, October
2005.


Source: reuters



comments powered by Disqus